Rhythm Control in AF: Have We Reached the Last Frontier?

AF is a worldwide epidemic, affecting approximately 33 million people, and its rising prevalence is expected to account for increasing clinical and public health costs. AF is associated with an increased risk of MI, heart failure, stroke, dementia, chronic kidney disease and mortality. Preserving si...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Gheorghe-Andrei Dan
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2019
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/89e0833035cd402797df4c1d51aaa7ef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:89e0833035cd402797df4c1d51aaa7ef
record_format	dspace
spelling	oai:doaj.org-article:89e0833035cd402797df4c1d51aaa7ef2021-12-04T16:01:38ZRhythm Control in AF: Have We Reached the Last Frontier?10.15420/ecr.2019.8.11758-37641758-3756https://doaj.org/article/89e0833035cd402797df4c1d51aaa7ef2019-07-01T00:00:00Zhttps://www.ecrjournal.com/articles/rhythm-control-in-atrial-fibrillationhttps://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764AF is a worldwide epidemic, affecting approximately 33 million people, and its rising prevalence is expected to account for increasing clinical and public health costs. AF is associated with an increased risk of MI, heart failure, stroke, dementia, chronic kidney disease and mortality. Preserving sinus rhythm is essential for a better outcome. However, because of the inherent limits of both pharmacological and interventional methods, rhythm strategy management is reserved for symptom and quality-of-life improvement. While ‘classical’ antiarrhythmic drug therapy remains the first-line therapy for rhythm control, its efficacy and safety are limited by empirical use, proarrhythmic risk and organ toxicity. Ablative techniques have had an impressive development, but AF ablation still failed to demonstrate a significant impact on hard endpoints. Understanding of the complex mechanisms of AF will help to develop new vulnerable targets to therapy. Promising molecules are under development, intended to fill the gap between the current pharmacological treatment aimed at maintaining sinus rhythm and the expectations from rhythm strategy.Gheorghe-Andrei DanRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 14, Iss 2, Pp 77-81 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Gheorghe-Andrei Dan Rhythm Control in AF: Have We Reached the Last Frontier?
description	AF is a worldwide epidemic, affecting approximately 33 million people, and its rising prevalence is expected to account for increasing clinical and public health costs. AF is associated with an increased risk of MI, heart failure, stroke, dementia, chronic kidney disease and mortality. Preserving sinus rhythm is essential for a better outcome. However, because of the inherent limits of both pharmacological and interventional methods, rhythm strategy management is reserved for symptom and quality-of-life improvement. While ‘classical’ antiarrhythmic drug therapy remains the first-line therapy for rhythm control, its efficacy and safety are limited by empirical use, proarrhythmic risk and organ toxicity. Ablative techniques have had an impressive development, but AF ablation still failed to demonstrate a significant impact on hard endpoints. Understanding of the complex mechanisms of AF will help to develop new vulnerable targets to therapy. Promising molecules are under development, intended to fill the gap between the current pharmacological treatment aimed at maintaining sinus rhythm and the expectations from rhythm strategy.
format	article
author	Gheorghe-Andrei Dan
author_facet	Gheorghe-Andrei Dan
author_sort	Gheorghe-Andrei Dan
title	Rhythm Control in AF: Have We Reached the Last Frontier?
title_short	Rhythm Control in AF: Have We Reached the Last Frontier?
title_full	Rhythm Control in AF: Have We Reached the Last Frontier?
title_fullStr	Rhythm Control in AF: Have We Reached the Last Frontier?
title_full_unstemmed	Rhythm Control in AF: Have We Reached the Last Frontier?
title_sort	rhythm control in af: have we reached the last frontier?
publisher	Radcliffe Medical Media
publishDate	2019
url	https://doaj.org/article/89e0833035cd402797df4c1d51aaa7ef
work_keys_str_mv	AT gheorgheandreidan rhythmcontrolinafhavewereachedthelastfrontier
_version_	1718372748337610752

Rhythm Control in AF: Have We Reached the Last Frontier?

Ejemplares similares